background
major
asthma
exacerb
relat
viral
respiratori
infect
previou
studi
report
low
interferon
respons
patient
asthma
increas
risk
virusinduc
exacerb
object
sought
determin
relationship
lower
airway
inflammatori
biomark
specif
interferon
gene
express
sever
presenc
exacerb
asthmat
experienc
natur
occur
viral
infect
method
sputum
sampl
analys
subject
asthma
exacerb
studi
experienc
confirm
viral
infect
subject
monitor
daili
symptom
medic
use
peak
expiratori
flow
rate
baselin
sputum
sampl
assess
cell
count
gene
express
result
interferon
gamma
express
significantli
greater
patient
asthma
exacerb
compar
nonexacerb
patient
p
ifnc
mrna
level
correl
peak
asthma
index
r
p
r
p
r
p
respect
addit
eosinophil
major
basic
protein
mrna
level
greater
patient
asthma
exacerb
compar
nonexacerb
patient
p
p
p
respect
mrna
correl
peak
asthma
index
p
conclus
find
indic
asthma
exacerb
associ
increas
rather
decreas
express
interferon
earli
cours
infect
find
rais
possibl
excess
virusinduc
interferon
product
acut
infect
contribut
airway
inflamm
exacerb
asthma
frequent
exacerb
asthma
adult
lead
acceler
declin
lung
function
contribut
morbid
studi
shown
asthma
exacerb
virusinduc
howev
viral
respiratori
infect
asthmat
result
exacerb
mechan
risk
factor
viral
respiratori
infect
transit
asthma
exacerb
well
establish
mani
inflammatori
mediat
induc
upon
viral
infect
includ
interferon
ifn
import
compon
host
defenc
viral
infect
instrument
engag
adapt
immun
respons
interferon
classifi
three
categori
type
ii
iii
express
type
interferon
ifna
famili
ifnb
type
iii
interferon
ifnk
famili
directli
trigger
virusinduc
signal
contrast
type
ii
interferon
ifnc
gener
express
cell
nk
cell
monocyt
respons
cytokin
rather
viral
particl
type
iii
interferon
express
sever
cell
type
includ
limit
bronchial
epitheli
cell
macrophag
fibroblast
plasmacytoid
dendrit
cell
interferon
initi
robust
antivir
respons
impair
viru
replic
celltocel
spread
viru
addit
studi
suggest
associ
asthma
interferon
defici
may
predispos
individu
virusinduc
exacerb
asthma
previous
report
quantit
level
viral
particl
upper
airway
correl
develop
asthma
exacerb
rather
extent
neutrophil
inflamm
induc
viral
infect
correspond
develop
sever
asthma
exacerb
addit
human
rhinoviru
hrv
preval
viral
respiratori
infect
respons
increas
asthma
symptom
exacerb
furthermor
hrv
infect
extend
lower
airway
suggest
virusinduc
cytokin
respons
lower
airway
may
directli
contribut
develop
sever
asthma
exacerb
induc
sputum
provid
sampl
lower
airway
inflammatori
milieu
dissect
link
exacerb
virus
measur
inflammatori
mediat
sputum
gene
express
sputum
cell
use
character
lower
airway
inflamm
examin
whether
presenc
sever
asthma
exacerb
correspond
lower
airway
inflammatori
respons
invok
viral
infect
examin
sputum
sampl
express
interferon
ifnc
asthma
patient
particip
studi
natur
occur
viral
upper
respiratori
infect
previous
describ
subject
particip
clinic
studi
viral
exacerb
asthma
viax
univers
wisconsin
institut
review
board
approv
protocol
protocol
includ
clinic
character
collect
induc
sputum
sampl
time
patient
initi
cold
follow
resolut
symptom
typic
week
later
consid
repres
baselin
see
support
inform
detail
figur
subject
enrol
studi
within
h
start
selfreport
cold
symptom
particip
asthma
elig
year
age
met
follow
criteria
physician
diagnosi
asthma
least
month
histori
wheez
asthma
exacerb
initi
cold
predict
time
first
visit
absenc
highdos
inhal
use
oral
corticosteroid
enrol
posit
skin
test
least
one
aeroallergen
exclus
criteria
includ
current
smoke
histori
packyear
preenrol
requir
puffsday
rescu
albuterol
concomit
use
two
asthma
control
agent
current
immunotherapi
analysi
includ
subset
studi
particip
complet
protocol
confirm
viral
infect
provid
sputum
sampl
enough
cell
mrna
isol
less
epitheli
cell
baselin
visit
acut
visit
cold
symptom
viru
detect
rhinoviru
molecular
type
quantif
viral
load
perform
previous
describ
briefli
sputum
sampl
nasal
lavag
sampl
extract
aliquot
cell
pellet
contain
cell
store
trizol
reagent
invitrogen
carlsbad
ca
usa
total
rna
revers
transcrib
cdna
respiratori
multicod
assay
eragen
bioscienc
madison
wi
usa
use
fluorimetr
detect
common
respiratori
virus
multiplex
polymeras
chang
reaction
pcr
flow
cytometri
sampl
posit
rhinovirus
partial
sequenc
determin
strain
induc
sputum
obtain
previous
describ
sputum
sampl
collect
within
day
enrol
follow
resolut
symptom
typic
week
later
briefli
patient
inhal
nebul
salin
min
rins
mouth
cough
collect
sputum
repeat
total
three
time
adequ
sputum
obtain
sputum
dilut
pb
sampl
centrifug
cell
pellet
collect
examin
cell
distribut
h
e
stain
slide
place
trizol
solut
rna
purif
sputum
supernat
mix
sputolysin
emd
millipor
darmstadt
germani
adequ
sputum
sampl
defin
least
wbc
per
sampl
acut
baselin
visit
epitheli
cell
contamin
less
sputum
cell
lysat
store
trizol
rna
isol
accord
manufactur
instruct
revers
transcrib
use
superscript
iii
life
technolog
grand
island
ny
usa
quantit
pcr
perform
combin
cdna
random
primer
nucleotid
rnasin
promega
madison
wi
usa
previous
describ
primer
probe
appli
biosytem
grand
island
ny
usa
ifnc
mbp
neutrophil
elastas
tgfb
combin
taqman
gene
express
mastermix
duplic
singleplex
realtim
pcr
steponeplu
pcr
system
appli
biosystem
result
calcul
use
method
rel
endogen
control
human
bglucuronidas
gusb
life
technolog
asthma
index
calcul
daili
previous
describ
use
worksheet
avail
articl
onlin
repositori
briefli
refer
even
peak
expiratori
flow
rate
pefr
total
asthma
symptom
score
valu
calcul
mean
data
stabl
week
resolut
visit
asthma
symptom
score
captur
rescu
bronchodil
use
nocturn
awaken
chest
tight
wheez
cough
dyspnoea
roll
averag
symptom
score
total
daili
percent
declin
rel
refer
pefr
compil
throughout
studi
enrol
captur
data
previou
h
asthma
index
calcul
serial
subtract
baselin
score
averag
score
asthma
index
score
greater
equal
previous
shown
consist
consensu
guidelin
definit
moder
exacerb
peak
asthma
index
refer
highest
valu
obtain
within
day
acut
visit
sputum
collect
associ
cytokin
level
peak
asthma
index
examin
use
linear
model
asthma
index
treat
continu
variabl
categor
variabl
ai
nonexacerb
vs
ai
exacerb
cytokin
level
logtransform
asthma
index
squareroot
transform
approxim
normal
analysi
pvalu
less
regard
statist
signific
analys
conduct
use
r
version
r
foundat
statist
comput
vienna
austria
sigmaplot
version
sysstat
softwar
san
jose
ca
usa
tabl
viru
identif
sequenc
rhinoviru
subgroup
demonstr
signific
differ
subject
without
exacerb
subject
exacerb
significantli
greater
reduct
peak
expiratori
flow
vs
p
exacerb
associ
signific
chang
cold
symptom
score
increas
significantli
baselin
acut
visit
exacerb
group
vs
p
cold
group
vs
p
exacerb
associ
increas
peak
asthma
index
median
rang
vs
rang
observ
compar
result
complet
viax
cohort
shown
tabl
signific
differ
baselin
sputum
eosinophil
neutrophil
lymphocyt
macrophag
experienc
exacerb
notabl
observ
exacerb
associ
significantli
greater
neutrophil
influx
previous
report
sputum
neutrophil
data
shown
median
interquartil
rang
indic
differ
acut
baselin
visit
repres
differ
p
acut
baselin
visit
within
group
repres
differ
p
exacerb
exacerb
significantli
greater
patient
virusinduc
exacerb
measur
greater
differ
mean
percent
p
mean
total
number
cell
cell
gram
p
shown
fig
ifnc
mrna
express
lower
airway
significantli
greater
p
exacerb
also
trend
exacerb
greater
express
p
p
mrna
addit
peak
asthma
index
correl
express
ifnc
mrna
sputum
cell
exacerb
p
p
p
respect
tabl
exacerb
also
associ
greater
express
mbp
mrna
sputum
sampl
p
p
p
respect
fig
addit
peak
asthma
index
correl
sputum
mrna
express
p
similar
trend
mbp
neutrophil
elastas
mrna
p
p
respect
tabl
object
studi
identifi
clinic
inflammatori
featur
airway
inflamm
measur
sputum
differenti
virusinduc
exacerb
uncompl
viral
cold
expect
exacerb
associ
greater
gene
express
inflammatori
gene
mediat
eosinophil
major
basic
protein
also
percentag
rhinoviru
isol
subject
well
subgroup
classif
consist
previou
observ
literatur
addit
find
indic
exacerb
associ
greater
express
ifnc
mrna
sputum
cell
furthermor
quantif
ifnc
sputum
gene
express
significantli
correl
quantit
measur
symptom
sever
asthma
index
sever
studi
report
interferon
respons
viral
infect
differ
asthma
patient
compar
healthi
control
howev
find
controversi
whether
differ
asthma
patient
healthi
control
due
defici
interferon
respons
viru
exagger
respons
clear
exampl
analys
vitro
cell
cultur
primari
bronchial
epitheli
cell
monocyt
alveolar
macrophag
deriv
asthma
patient
quantif
gene
express
compar
categor
subject
exacerb
vs
exacerb
base
asthma
index
mrna
quantif
normal
logtransform
pvalu
comparison
shown
data
shown
median
interquartil
rang
quantif
gene
express
normal
logtransform
also
analys
linear
regress
peak
asthma
index
continu
variabl
correl
coeffici
pvalu
shown
infect
hrv
shown
diminish
ifnk
c
b
respons
compar
cell
deriv
control
nonasthma
patient
furthermor
patient
lower
ifnk
releas
vitroinfect
bal
cell
exhibit
greater
drop
follow
experiment
hrv
inocul
asthma
patient
current
experienc
exacerb
viral
infect
sputum
gene
express
ifnk
invers
correl
asthma
symptom
score
defici
interferon
product
thought
increas
suscept
asthmat
develop
viral
infect
lower
airway
contrast
studi
demonstr
asthma
associ
intact
interferon
respons
posit
associ
lower
airway
symptom
ifnc
protein
level
nasal
lavag
sampl
atop
asthma
patient
healthi
control
exhibit
compar
increas
experiment
inocul
interestingli
one
studi
report
asthma
symptom
relat
lower
express
ifnk
mrna
increas
express
ifnk
sputum
cell
addit
ifnk
protein
mrna
express
upper
airway
respiratori
secret
increas
wheez
adolesc
viral
infect
compar
nonwheez
correl
sever
wheez
ill
data
consist
latter
find
shown
increas
lower
airway
express
ifnb
ifnc
experienc
exacerb
furthermor
ifnc
show
signific
correl
quantif
asthma
symptom
sever
measur
peak
asthma
index
data
suggest
possibl
vigor
interferon
respons
viral
respiratori
infect
could
contribut
develop
sever
asthma
exacerb
conceptu
interferon
express
may
serv
two
role
first
onset
viral
exposur
interferon
may
protect
sever
infect
second
infect
occur
interferon
may
contribut
promot
inflammatori
cascad
airway
contribut
increas
asthma
symptom
studi
sever
novel
featur
focus
gene
express
biomark
inflammatori
milieu
lower
airway
examin
asthma
patient
natur
occur
viral
infect
final
util
quantit
measur
asthma
symptom
sever
asthma
index
incorpor
subject
object
measur
control
notabl
gene
express
data
mbp
consist
publish
observ
protein
express
relat
product
airway
provid
valid
use
sputum
cell
gene
express
surrog
biomark
respect
cytokin
mediat
one
limit
studi
inabl
identifi
cell
type
respons
chang
gene
express
therefor
chang
mrna
express
may
result
either
increas
transcript
per
cell
fluctuat
cellular
composit
also
analysi
focus
gene
express
confirmatori
studi
protein
secret
need
hand
use
rtpcr
sensit
method
quantifi
gene
express
possibl
mani
protein
detect
sputum
either
due
low
level
protein
express
lack
sensitivespecif
reagent
readili
assess
mrna
level
addit
sputum
cell
sampl
mainli
consist
leucocyt
data
may
reflect
chang
epitheli
cell
gene
express
studi
conduct
group
mild
asthmat
experienc
exacerb
requir
oral
prednison
visit
emerg
depart
given
limit
notabl
abl
detect
signific
associ
interferon
express
exacerb
sever
specul
find
extrapol
sever
exacerb
remain
test
also
unknown
whether
chang
interferon
respons
asthmat
patient
differ
control
nonasthmat
popul
summari
viral
infect
induc
express
interferon
wellrecogn
antivir
properti
data
suggest
earli
acut
phase
virusinduc
exacerb
asthma
interferon
respons
increas
rel
uncompl
cold
causal
associ
remain
determin
suggest
either
sever
ill
induc
greater
interferon
respons
altern
exuber
virusinduc
interferon
respons
contribut
airway
inflamm
exacerb
asthma
